HealthQuill Antibody-drug conjugate
The US Food and Drug Administration (FDA) has granted an accelerated approval for AbbVie Inc.’s drug to treat a specific group of adult lung cancer patients who have tried other systemic treatments.
Drugs Health Pharma

AbbVie’s NSCLC lung cancer drug gets accelerated approval from FDA

 HQ Team May 15, 2025: The US Food and Drug Administration (FDA) has granted an accelerated approval for AbbVie Inc.’s drug to treat.

Read More
Samsung Biologics has announced a $1.24 billion manufacturing deal with an unnamed Asian pharmaceutical company.
Drugs Health Pharma

CDMO Samsung Biologics signs $1.24 billion drug manufacturing deal

Samsung Biologics has announced a $1.24 billion manufacturing deal with an unnamed Asian pharmaceutical company.

Read More
AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of breast cancer in the US.
Drugs Health Pharma

AstraZeneca, Daiichi’s Enhertu drug gets FDA’s priority review in US

AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of.

Read More
The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat a type of lung cancer.
Drugs Health Pharma

FDA rejects Daiichi, Merck, antibody-drug conjugate application

The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat.

Read More